These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

365 related items for PubMed ID: 19606071

  • 1. Current role of bevacizumab in colorectal cancer.
    Saltz L.
    Clin Adv Hematol Oncol; 2009 Jun; 7(6):375-6. PubMed ID: 19606071
    [No Abstract] [Full Text] [Related]

  • 2. The use cetuximab after oxaliplatin-based chemotherapy in a patient with metastatic colorectal cancer.
    Malik Z, Eng C.
    Clin Adv Hematol Oncol; 2007 Jan; 5(1 Suppl 1):4-7. PubMed ID: 17491584
    [No Abstract] [Full Text] [Related]

  • 3. Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer.
    Dohn LH, Jensen BV, Larsen FO.
    Acta Oncol; 2010 Apr; 49(3):395-6. PubMed ID: 20001495
    [No Abstract] [Full Text] [Related]

  • 4. Bevacizumab in the treatment of colorectal cancer.
    Marshall JL.
    Clin Adv Hematol Oncol; 2007 Jan; 5(1 Suppl 1):8-9. PubMed ID: 17491585
    [No Abstract] [Full Text] [Related]

  • 5. Dual biologic therapy in the first-line mCRC setting: implications of the CAIRO2 study.
    Chu E.
    Clin Colorectal Cancer; 2008 Jul; 7(4):226. PubMed ID: 18650190
    [No Abstract] [Full Text] [Related]

  • 6. The treatment of colorectal carcinoma: standard chemotherapy and beyond.
    Eng C, Abbruzzese JL.
    Clin Adv Hematol Oncol; 2004 Sep; 2(9):592-8. PubMed ID: 16163242
    [Abstract] [Full Text] [Related]

  • 7. [Advances in the treatment of metastatic colorectal cancer with bevacizumab].
    Longo F, Mansueto G.
    Tumori; 2006 Sep; 92(5):suppl 1-12. PubMed ID: 17168449
    [No Abstract] [Full Text] [Related]

  • 8. Perforating dermatosis in a patient receiving bevacizumab.
    Vano-Galvan S, Moreno C, Medina J, Pérez-García B, García-López JL, Jaén P.
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):972-4. PubMed ID: 19470057
    [No Abstract] [Full Text] [Related]

  • 9. Liver resection after FOLFOX with bevacizumab.
    Mickle M, Mulcahy MF.
    Clin Adv Hematol Oncol; 2007 Jan; 5(1 Suppl 1):12-4. PubMed ID: 17491587
    [No Abstract] [Full Text] [Related]

  • 10. Bevacizumab in advanced colorectal cancer: a challenge to the current paradigm.
    Booth C.
    J Clin Oncol; 2008 Oct 01; 26(28):4693-4; author reply 4694-5. PubMed ID: 18824719
    [No Abstract] [Full Text] [Related]

  • 11. Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX.
    Klinger M, Tamandl D, Eipeldauer S, Hacker S, Herberger B, Kaczirek K, Dorfmeister M, Gruenberger B, Gruenberger T.
    Ann Surg Oncol; 2010 Aug 01; 17(8):2059-65. PubMed ID: 20177795
    [Abstract] [Full Text] [Related]

  • 12. Accrual delayed in adjuvant bevacizumab trial.
    Tuma RS.
    J Natl Cancer Inst; 2006 Apr 05; 98(7):439-40. PubMed ID: 16595779
    [No Abstract] [Full Text] [Related]

  • 13. [Angiogenesis targeting in gastro-intestinal cancers].
    Meric JB.
    Bull Cancer; 2007 Apr 05; 94(7 Suppl):F207-15. PubMed ID: 17964998
    [Abstract] [Full Text] [Related]

  • 14. [The development of the first line treatment of metastatic colorectal cancer (mCRC)].
    Landherr L, Nagykálnai T.
    Magy Onkol; 2009 Sep 05; 53(3):237-46. PubMed ID: 19793687
    [Abstract] [Full Text] [Related]

  • 15. Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer.
    Hurwitz H, Kabbinavar F.
    Oncology; 2005 Sep 05; 69 Suppl 3():17-24. PubMed ID: 16301832
    [Abstract] [Full Text] [Related]

  • 16. [Bevacizumab in the treatment of colorectal carcinoma: news from ASCO 2008].
    Mansueto G, Longo F.
    Tumori; 2008 Sep 05; 94(4):suppl 1-14. PubMed ID: 18822711
    [No Abstract] [Full Text] [Related]

  • 17. Pathologic complete response to neoadjuvant FOLFOX in combination with bevacizumab in unresectable metastatic colorectal carcinoma.
    Duffy A, Shia J, Huitzil-Melendez FD, Fong Y, O'Reilly EM.
    Clin Colorectal Cancer; 2008 Mar 05; 7(2):140-3. PubMed ID: 18501074
    [Abstract] [Full Text] [Related]

  • 18. [Chemotherapy with bevacizumab (BV)+modified FOLFOX6 for unresectable colorectal cancer].
    Matsumoto R, Kuroda T, Yamada H, Hasegawa K, Mamiya Y, Kon A.
    Gan To Kagaku Ryoho; 2009 Nov 05; 36(12):2207-9. PubMed ID: 20037372
    [Abstract] [Full Text] [Related]

  • 19. First description of an uterine perforation potentially imputable to treatment with bevacizumab.
    Uguen T, Leconte B, Desgrippes R, Tchoundeu B, Bretagne JF, Manfredi S.
    Acta Oncol; 2012 Nov 05; 51(8):1102-4. PubMed ID: 23020310
    [No Abstract] [Full Text] [Related]

  • 20. Optimizing oxaliplatin-based therapy in metastatic colorectal cancer.
    Cassidy J.
    Clin Adv Hematol Oncol; 2008 May 05; 6(5):360-1. PubMed ID: 18516025
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.